GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Titan Pharmaceuticals Inc (NAS:TTNP) » Definitions » Price-to-Free-Cash-Flow

Titan Pharmaceuticals (Titan Pharmaceuticals) Price-to-Free-Cash-Flow : N/A (As of Jun. 02, 2024)


View and export this data going back to 1996. Start your Free Trial

What is Titan Pharmaceuticals Price-to-Free-Cash-Flow?

As of today (2024-06-02), Titan Pharmaceuticals's share price is $6.5102. Titan Pharmaceuticals's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Mar. 2024 was $-7.61. Hence, Titan Pharmaceuticals's Price-to-Free-Cash-Flow Ratio for today is N/A.

The historical rank and industry rank for Titan Pharmaceuticals's Price-to-Free-Cash-Flow or its related term are showing as below:

During the past 13 years, Titan Pharmaceuticals's highest Price-to-Free-Cash-Flow Ratio was 272.82. The lowest was 9.14. And the median was 14.97.

TTNP's Price-to-Free-Cash-Flow is not ranked *
in the Biotechnology industry.
Industry Median: 30.975
* Ranked among companies with meaningful Price-to-Free-Cash-Flow only.

Titan Pharmaceuticals's Free Cash Flow per Share for the three months ended in Mar. 2024 was $-0.72. Its Free Cash Flow per Share for the trailing twelve months (TTM) ended in was $-7.61.

During the past 3 years, the average Free Cash Flow per Share Growth Rate was 53.50% per year. During the past 5 years, the average Free Cash Flow per Share Growth Rate was 63.80% per year.

During the past 13 years, Titan Pharmaceuticals's highest 3-Year average Free Cash Flow per Share Growth Rate was 74.50% per year. The lowest was -39.40% per year. And the median was 14.50% per year.


Titan Pharmaceuticals Price-to-Free-Cash-Flow Historical Data

The historical data trend for Titan Pharmaceuticals's Price-to-Free-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Titan Pharmaceuticals Price-to-Free-Cash-Flow Chart

Titan Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Free-Cash-Flow
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Titan Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Price-to-Free-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Titan Pharmaceuticals's Price-to-Free-Cash-Flow

For the Biotechnology subindustry, Titan Pharmaceuticals's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Titan Pharmaceuticals's Price-to-Free-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Titan Pharmaceuticals's Price-to-Free-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Titan Pharmaceuticals's Price-to-Free-Cash-Flow falls into.



Titan Pharmaceuticals Price-to-Free-Cash-Flow Calculation

Titan Pharmaceuticals's Price-to-Free-Cash-Flow ratio for today is calculated as

Price-to-Free-Cash-Flow Ratio=Share Price/ Free Cash Flow per Share (TTM)
=6.5102/-7.614
=N/A

Titan Pharmaceuticals's Share Price of today is $6.5102.
Titan Pharmaceuticals's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-7.61.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

Price-to-Free-Cash-Flow Ratio=Market Cap/Free Cash Flow

Titan Pharmaceuticals  (NAS:TTNP) Price-to-Free-Cash-Flow Explanation

Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.

In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.


Be Aware

In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.


Titan Pharmaceuticals Price-to-Free-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Titan Pharmaceuticals's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Titan Pharmaceuticals (Titan Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
400 Oyster Point Boulevard, Suite 505, South San Francisco, CA, USA, 94080
Titan Pharmaceuticals Inc is a pharmaceutical company developing therapeutics utilizing its proprietary long-term drug delivery platform, ProNeura, for the treatment of select chronic diseases for which steady state delivery of a drug provides efficacy and/or safety benefit. ProNeura consists of a small, solid implant made from a mixture of ethylene-vinyl acetate, or EVA, and a drug substance. Its first product based on ProNeura technology was the Probuphine (buprenorphine) implant, which was approved in the United States, Canada and the European Union, for the maintenance treatment of opioid use disorder in clinically stable patients taking 8 mg or less a day of oral buprenorphine.
Executives
Seow Gim Shen 10 percent owner NO. 4, FRANKY BUILDING, PROVIDENCE INDUSTRIAL ESTATE, MAHE T2 00000
Sire Group Ltd. 10 percent owner NO. 4, FRANKY BUILDING, PROVIDENCE INDUSTRIAL ESTATE, MAHE T2 00000
David Natan director 11190 BISCAYNE BLVD, MIAMI FL 33181
Matthew Charles Mcmurdo director 1047 SEWARD AVE., WESTFIELD NJ 07090
Peter Louis Chasey director 3295 N. FORT APACHE ROAD, STE. 110, LAS VEGAS NV 89129
Eric Howard Greenberg director 710 CARLYLE ST, WOODMERE NY 11598
Avraham Ben-tzvi director 44 ZAYT SHEMEN ST., FLAT 4, EFRAT L3 9045544
Katherine Beebe director, officer: President and COO 400 OYSTER POINT BLVD, SUITE 505, SOUTH SAN FRANCISCO CA 94080
Choon Hau Choong 10 percent owner NO. 23 LORONG TERUBONG RIA 2,, PAYA TERUBONG, GEORGE TOWN N8 11060
David E. Lazar director, 10 percent owner, officer: Chief Executive Officer VILLA 1, 14-43RD STREET, JUMEIRAH 2, DUBAI C0 00000
Activist Investing Llc other: Member of 10% owner group 1185 AVENUE OF THE AMERICAS, 3RD FLOOR., NEW YORK NY 10036
Joseph A Akers director 630 FIFTH AVENUE, 22ND FLOOR, NEW YORK NY 10111
James R Mcnab director C/O CURIS, INC, 4 MAGUIRE ROAD, LEXINGTON MA 02421
Marc Rubin director, officer: Executive Chairman C/O TITAN PHARMACEUTICALS, INC., 400 OYSTER POINT BLVD., STE 505, SAN FRANCISCO CA 94080
Dane Hallberg officer: See Remarks 400 OYSTER POINT BLVD., SUITE 505, SOUTH SAN FRANCISCO CA 94080